Skip to content
Open access

Zinc-mediated lysosomal activation by 1H10 enhances autophagy and attenuates tau pathology in Alzheimer's disease models.

Jul 2026 · Molecular Brain · 0 citations
Medicine

TL;DR

Findings indicate that zinc-mediated lysosomal activation by 1H10 enhances the autophagy-lysosomal pathway and attenuates tau pathology in AD models, suggesting that targeting lysosomal function may represent a potential therapeutic strategy for neurodegenerative disorders characterized by impaired proteostasis.

Abstract

Impaired autophagic flux and lysosomal dysfunction contribute critically to the accumulation of pathological protein aggregates in Alzheimer's disease (AD). Emerging evidence suggests that intracellular zinc dynamics regulate lysosomal function by modulating processes such as acidification and lysosomal biogenesis. We previously identified 1H10 as an AMP-activated protein kinase (AMPK) inhibitor and subsequently demonstrated its zinc-binding capacity and ability to regulate intracellular zinc homeostasis. Building on our prior findings that intra-lysosomal zinc promotes acidification and activates transcription factor EB (TFEB), we investigated whether 1H10 enhances lysosomal function through zinc mobilization in neurons, thereby improving autophagy and reducing pathological protein accumulation. In primary cortical neurons, 1H10 increased lysosomal abundance and enhanced lysosomal degradative capacity in a zinc-dependent manner, as demonstrated by increased cathepsin B activity and DQ-BSA degradation. It alleviated lysosomal dysfunction induced by v-ATPase inhibition and promoted autophagic flux, leading to reduced accumulation of amyloid-β (Aβ) and tau in neuronal models. In 5XFAD mice, 1H10 treatment showed trends toward improved spatial learning in the Morris water maze, reduced tau phosphorylation at Thr205 and Ser214, normalized LC3-II levels, and restored autophagic-lysosomal homeostasis, without significant changes in extracellular amyloid plaque burden. These findings indicate that zinc-mediated lysosomal activation by 1H10 enhances the autophagy-lysosomal pathway and attenuates tau pathology in AD models, suggesting that targeting lysosomal function may represent a potential therapeutic strategy for neurodegenerative disorders characterized by impaired proteostasis.

Read PDF

Similar papers

Review Jul 2026

Mechanisms of autophagy–lysosome pathway impairment in Alzheimer's disease

It is suggested that enhancing or improving autophagy function may be an effective treatment method to alleviate the condition of AD patients, which can provide new strategies for clinical treatment and intervention of AD in the future.

Kun Lu, Yirui Lu, Runyu Tang et al. · 0 citations
Open access Jul 2026

Mitochondrial accumulation and lysosomal dysfunction result in mitochondrial plaques in Alzheimer's disease.

It is shown that AD model mice expressing a mitophagy reporter (APP/PSEN1/mt-Keima) develop large accumulation of acidic and neutral mitochondria within neuronal processes that form a previously unrecognized pathological structure termed mitochondrial plaques (MPs).

Xiuli Dan, D. L. Croteau, Wenlong Liu et al. · 1 citation
Open access Jul 2026

TRPML1 loss drives lysosomal calcium failure and astrocyte dysfunction across Alzheimer’s Disease progression

It is found that astrocytic cytosolic calcium activity is suppressed prior to amyloid plaque deposition and is accompanied by reduced lysosomal acidification in vivo, identifying lysosomal failure as an initiating event in astrocyte dysfunction in AD.

D. Shah, P. Desai, C. Chertavian et al. · 0 citations
Review 2026

Bioenergetic impairment-induced Tau acetylation: Converging pathways in Alzheimer's disease.

Understanding the metabolic pathways that drive tau acetylation may offer new therapeutic targets aimed at restoring neuronal energy balance, re-establishing acetylation homeostasis, and potentially slowing the progression of AD.

Basavaraju K. C., Poornima Priyadarshini · 0 citations
Open access Jul 2026

IL17A disrupts autophagy-lysosomal function and lysosome reformation through the GSK3B-TFE3 signaling pathway in Huntington disease.

Therapeutic neutralization of IL17A with a monoclonal antibody (IL17A mAb) ameliorates disease phenotypes in R6/2 HD mice, improving motor performance, extending survival, and reducing gliosis, and highlights IL17A inhibition as a promising therapeutic strategy for targeting autophagy-lysosomal dysfunction in HD.

Kai-Po Chen, Tz-Chuen Ju · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.